A systematic review of inter-individual differences in the DNA repair processes involved in melphalan monoadduct repair in relation to treatment outcomes Maia van KanKathryn E. BurnsNuala A. Helsby Review Article 04 August 2021 Pages: 755 - 769
The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update Zahra TorkiDavood GhaviMohammad Reza Alivand Review Article 12 September 2021 Pages: 771 - 793
Antitumor efficacy of CHMFL-KIT-110 solid dispersion in mouse xenograft models of human gastrointestinal stromal tumors Shengfu WangChunyan WangShangxue Yan Original Article 26 July 2021 Pages: 795 - 804
Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck Sema Sezgin GöksuAli Murat TatlıHasan Şenol Coşkun Original Article 26 July 2021 Pages: 805 - 812
Predictive value of ERCC2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy Goretti DuranRaquel CruzMaría Jesús Lamas Original Article 26 July 2021 Pages: 813 - 823
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment Mehmet AkceAnthony El-KhoueiryCindy L. O’Bryant Original Article Open access 29 July 2021 Pages: 825 - 836
Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon Marianne Rodrigues FernandesJuliana Carla Gomes RodriguesNey Pereira Carneiro dos Santos Original Article 31 July 2021 Pages: 837 - 844
Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells Marielle HuotMaxime CaronNoël J. M. Raynal Original Article 31 July 2021 Pages: 845 - 856
Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease Toshihito OtaniKakuhiro YamaguchiNoboru Hattori Original Article 04 August 2021 Pages: 857 - 865
Minimal PK/PD model for simultaneous description of the maximal tolerated dose and metronomic treatment outcomes in mouse tumor models Ivan N. TerterovVyacheslav A. ChubenkoAlexey A. Bogdanov Original Article 05 August 2021 Pages: 867 - 878
A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects Vladimir HanesVincent ChowAdeep Puri Original Article Open access 05 August 2021 Pages: 879 - 886
A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors Mingxiang LiaoKrzysztof G. JeziorskiJim J. Xiao Original Article Open access 09 August 2021 Pages: 887 - 897
Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials Hong XiangLucy LiuHelen Collins Original Article Open access 12 August 2021 Pages: 899 - 910
Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study Linea Natalie ToksvangLiv Andrés-JensenKjeld Schmiegelow Short Communication 18 June 2021 Pages: 911 - 917
Comment on “Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase” Wing H. Tong Letter to the Editor 01 September 2021 Pages: 919 - 920
